December 05, 2024
Translink Corporate Finance in Germany advised Marinomed Biotech AG, a renowned biopharmaceutical company in the field of respiratory diseases listed on the Vienna Stock Exchange, on the sale of its Carragelose portfolio to Unither Pharmaceuticals SAS. The transaction terms include upfront and milestone payments in total of up to EUR 20 million, including an upfront payment of up to EUR 5 million.
Further payments depend on the achievement of defined commercial and operational targets over the next two years. Closing of the transaction is subject to typical conditions such as merger control and the approval by the company’s shareholders at an extraordinary general meeting. The agreement provides for the transfer of the entire Carragelose portfolio, including all associated agreements. As part of the agreement, Marinomed and Unither also entered into a transition service agreement. The proceeds from the sale of the Carragelose business will be sufficient to finance the operating business, with increased focus on the Marinosolv platform. The acquisition provides Unither with an innovative product platform with high growth potential and further growth opportunities for the Carrageenan portfolio.
“Unither Pharmaceuticals is a leading contract development and manufacturing organisation of medical devices and pharmaceutical products with production sites in many parts of the world. The collaboration with Unither offers an excellent development and growth opportunity for the Carragelose portfolio. With the help of Translink Germany, I am convinced that we have found the ideal partner for our business”, says Andreas Grassauer, CEO of Marinomed.
“In order to find the best possible future for Marinomed’s Carragelose portfolio, we conducted an extensive search process for the ideal strategic partner utilising our international network of healthcare specialists. With Unither, Marinomed has found a strong partner who will be able to capitalise on the Carragelose products treating allergy and the recently developed Carragelose eye drops”, says Christian Fest, Partner of Translink Germany.
Contact our Team:
Translink Corporate Finance is a world leader in cross-border mid-market M&A advisory services, specialising in transactions ranging from €10M to €250M. Established in 1972, with over five decades of experience, we get the deal done. We are a trusted global group with over 400 experts worldwide, and a proven track record with long-standing clients and deep sector specific knowledge. At Translink Corporate Finance, we are easy to approach, and our core ethos revolves around the pursuit of sustainable value creation for our clients – whose best interests always come first.
Translink Corporate Finance GmbH & Co. KG with its offices in Berlin, Bremen, Cologne, and Frankfurt, covers Translink’s business in Germany, Austria, and Switzerland. It is composed of seasoned finance and M&A professionals who have a strong record in advising companies in the healthcare sector on strategic transactions as well as in-depth experience in a variety of other sectors and disciplines. Visit Translink Corporate Finance Germany
Acting for over 50 years, Translink Corporate Finance is a global leader in SmidCap M&A (valuations ranging from €10 to 250 million), bringing together over 400 investment bankers in more than 35 countries. In France, the team consists of more than 20 professionals dedicated to M&A and financing operations, possessing sector-specific expertise in TMT, business services, healthcare, industrials, and energy. Visit Translink Corporate Finance France
TRANSLINK INTERNATIONAL AG
